CAR T cell immunotherapy for human cancer

Paper

Abstract

Adoptive T cell transfer (ACT) is a new area of transfusion medicine involving the infusion of lymphocytes to mediate antitumor, antiviral, or anti-inflammatory effects. The field has rapidly advanced from a promising form of immuno-oncology in preclinical models to the recent commercial approvals of chimeric antigen receptor (CAR) T cells to treat leukemia and lymphoma. This Review describes opportunities and challenges for entering mainstream oncology that presently face the CAR T field, with a focus on the challenges that have emerged over the past several years.

Analysis

Paper intelligence

Summary

This review discusses the advancements, opportunities, and challenges of Chimeric Antigen Receptor (CAR) T cell therapy in treating human cancers, particularly leukemia and lymphoma.

Key findings

CAR T cell therapy has progressed from preclinical models to commercial approvals for leukemia and lymphoma.
The field faces challenges in efficacy and safety as it aims for mainstream oncology adoption.

Limitations

Challenges in efficacy and safety need to be addressed for broader clinical application.

Applications

Treatment of leukemia
Treatment of lymphoma

Confidence100%

Discovery

Related papers

2027PubMed

Nucleofection-Based CRISPR/Cas Delivery in Human T Cells for Immunotherapy Applications.

Ortiz-Bueno M; Millán-López A; Labun K; Benabdellah K

Jan 1, 2027Methods in molecular biology (Clifton, N.J.)

2027PubMed

Harnessing necroptosis via RIPK1 degradation to potentiate radio-immunotherapy in cervical cancer.

Wu T; Lv B; Wang H; He G; Fu Y; Ji X; Zeng Y; Ni D; Qiu J; Hua K

Jan 1, 2027Bioactive materials

2026arXiv

Combining standard chemoradiotherapy with CAR-T cell therapy in malignant gliomas: Insights from an impulsive mathematical framework and virtual trials

Dmitry Sinelshchikov; Nikols Amaru Mora Millán; Miguel Perales-Patón; Juan Belmonte-Beitia; Matteo Italia

Sep 30, 2026

2026Crossref0 citations

CAR-Mix cell therapies to treat solid tumors by providing synergistic interaction between engineered macrophages and polyclonal T cells.

Xudong Wang; Jin Zhang

Jun 1, 2026Journal of Clinical Oncology

2026Semantic Scholar0 citations

Integration site analysis in engineered T cell therapies: what we measure, what we miss, and what regulators expect

Deividas Pažėraitis; J. Kupčinskas

Feb 23, 2026Cell and Gene Therapy Insights0 influential

2026PubMed

Oncolytic virus-mediated GPC3 delivery overcomes antigen heterogeneity in hepatocellular carcinoma and enhances GPC3-directed immunotherapy.

Chaurasiya S; Kim SI; Sah P; Zhang Z; Vashi Y; Wu H; Cillis J; Park A; Yang A; Woo Y; Xiong G; Liu J; Zhang H; Wang P; Liu C; Fong Y

Jan 1, 2026Frontiers in immunology

Source record

Publication metadata

Authors: Carl H. June; Roddy S. O’Connor; Omkar U. Kawalekar; Saba Ghassemi; Michael C. Milone
Published: Mar 22, 2018
Journal or venue: Science
DOI: 10.1126/science.aar6711
Paper type: journal article
Source: Openalex

DOI OpenAlex